<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00143013</url>
  </required_header>
  <id_info>
    <org_study_id>002</org_study_id>
    <nct_id>NCT00143013</nct_id>
  </id_info>
  <brief_title>Gene Expression Profiling and Bioinformatic Analysis Identifying Genes and Biochemical Pathways in Type 2 Diabetes</brief_title>
  <official_title>Gene Expression Profiling by DNA Chips and Subsequent Bioinformatic Analysis for Identification of Genes and Biochemical Pathways Associated With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <brief_summary>
    <textblock>
      Type 2 diabetes is a disorder of the metabolic system that greatly affects individual health&#xD;
      and imposes significant cost for society on health care. It is necessary to initiate research&#xD;
      with emphasis on improvement on quality of life and reduce the serious complications as a&#xD;
      result of type 2 diabetes.&#xD;
&#xD;
      In type 2 diabetes insulin resistance and impairment of insulin secretion by beta-cells are&#xD;
      the major pathophysiological defects and characterized by raised plasma glucose levels.&#xD;
      Today, little is known about gene regulation and biochemical pathways involved in the&#xD;
      disease.&#xD;
&#xD;
      Bioinformatics and gene expression microarrays (GEM) will be applied to gain insight into the&#xD;
      molecular pathophysiology of type 2 diabetes. The simultaneous monitoring of thousands of&#xD;
      genes in parallel can identify novel genes and entire biochemical pathways that are&#xD;
      dysregulated at the transcriptional level. Affymetrix Inc. chips or spotted arrays will be&#xD;
      applied as DNA microarray tools. Bioinformatic software programs and databases will be&#xD;
      employed as data mining tools in order to perform statistical analysis, cluster analysis and&#xD;
      biochemical pathway analysis.&#xD;
&#xD;
      Biopsies from skeletal muscle and adipose tissue from both diabetics and nondiabetics will be&#xD;
      applied. Changes in genes and biochemical pathways between diabetics and nondiabetics and&#xD;
      functional relationships between adipose tissue and skeletal muscle will be investigated.&#xD;
&#xD;
      Grouping of subtypes in type 2 diabetes will be performed and a classification system will be&#xD;
      constructed. Building a classifier may provide better and more precise diagnosis of type 2&#xD;
      diabetes.&#xD;
&#xD;
      Major advances in health science of type 2 diabetes thus seems to be promising and paving the&#xD;
      way for individual treatment based on a more precise diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2004</start_date>
  <completion_date>April 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Of diabetic subjects:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Age: 30-65 years&#xD;
&#xD;
          -  BMI: 27-35&#xD;
&#xD;
        Of nondiabetic subjects:&#xD;
&#xD;
          -  Age: 30-65 years&#xD;
&#xD;
          -  BMI: 27-35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Of diabetic subjects:&#xD;
&#xD;
          -  Medication, which have any influence on glucose metabolism and gene expression in&#xD;
             adipose tissue and skeletal muscle at the time of sampling of biopsies.&#xD;
&#xD;
          -  Disease in liver, heart, vessels or endocrine organs&#xD;
&#xD;
        Of nondiabetic subjects:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Relatives with type 2 diabetes&#xD;
&#xD;
          -  Hyperglycemia&#xD;
&#xD;
          -  Medication, which have any influence on glucose metabolism and gene expression in&#xD;
             adipose tissue and skeletal muscle at the time of sampling of biopsies.&#xD;
&#xD;
          -  Disease in liver, heart, vessels or endocrine organs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vibe Skov, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vibe Skov, PhD</last_name>
    <email>vibe.skov@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Biochemistry and Genetics, KKA</name>
      <address>
        <city>Odense C</city>
        <state>Funen</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vibe Skov, MSc</last_name>
      <phone>+45 6541 2837</phone>
      <email>vibe.skov@ouh.fyns-amt.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>June 11, 2008</last_update_submitted>
  <last_update_submitted_qc>June 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2008</last_update_posted>
  <keyword>type 2 diabetes</keyword>
  <keyword>microarray</keyword>
  <keyword>skeletal muscle</keyword>
  <keyword>bioinformatics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

